Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Mankind Pharma Limited (NSE: MANKIND), ISIN INE634S01028 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
MANKIND last traded at ₹2660.45 (+4.74%), with a 52-week range of ₹1909.70 to ₹2705.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 72.62%, FIIs 9.37%, DIIs 15.54%, mutual funds 11.31%.
EquiSense Score (ECS): 75/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.